22 peptides tracked
Australia's
Independent
Peptide Register
No vendors. No affiliates. Just data.
Fig. 01
Regulatory Status · May 2026
Retatrutide2
GHK-Cu10
Semaglutide12
Tirzepatide8
BPC-15718
CJC-129515
22
Peptides tracked
40
Prescription providers
52
Observed suppliers
1
Prohibited (S9)
01Intelligence
Peptide Status
TGA scheduling, enforcement trends, and access pathways for each peptide. Updated June 2026.
Editorial position: We recommend accessing peptides through an AHPRA-registered medical practitioner and TGA-licensed compounding pharmacy. This ensures clinical oversight, pharmaceutical-grade compounding, and legal compliance.
Retatrutide
Triple Agonist (GLP-1/GIP/Glucagon)
GHK-Cu
Copper Peptide
Semaglutide
GLP-1 Agonist
Tirzepatide
GLP-1/GIP Agonist
BPC-157
Tissue Repair
CJC-1295
Growth Hormone Secretagogue
Ipamorelin
Growth Hormone Secretagogue
TB-500
Tissue Repair
Melanotan II
Melanocortin Agonist
PT-141 (Bremelanotide)
Melanocortin Agonist
MOTS-c
Mitochondrial Peptide
Thymosin Alpha-1
Immune Modulator
KPV
Anti-inflammatory Peptide
Epithalon
Telomerase Activator
Gonadorelin
Hormonal Support
Dihexa
Cognitive Enhancement
02News
Regulatory Feed
Latest scheduling changes, enforcement actions, and market developments across all tracked peptides.
HeadlineSourceDate
GLP-1-based therapy and ICD-10-documented heart failure or respiratory failure events in non-diabetic adults with rheumatoid arthritis and obesity: a TriNetX federated cohort study.Semaglutide
Clinical rheumatology11 June 2026Clinical evidence of semaglutide for metabolic dysfunction-associated steatotic liver disease (MASLD): An updated meta-analysis.Semaglutide
British journal of clinical pharmacology11 June 2026Sustained Glycaemic Control and Preserved Beta-Cell Function in Newly Diagnosed Type 1 Diabetes Treated With Semaglutide.Semaglutide
Diabetes/metabolism research and reviews11 June 2026Towards Sustainable Synthesis of Peptide Therapeutics via Tag-Assisted Peptide Synthesis and Aryl Selenoester Aminolysis Ligation.Tirzepatide
Journal of the American Chemical Society11 June 2026Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity.Tirzepatide
Arthritis & rheumatology (Hoboken, N.J.)11 June 2026GLP-1 receptor agonist adjunct therapy stabilises Ramadan dysglycaemia in insulin-treated diabetes: a CGM-based study.Semaglutide
Diabetes research and clinical practice10 June 2026SGLT2 inhibitors and incretin-based therapies for metabolic dysfunction-associated steatohepatitis: a systematic review.Tirzepatide
European journal of clinical pharmacology10 June 2026Semaglutide-induced loss of skeletal muscle mass is blunted by co-administration of ketone estersSemaglutide
JCI Insight9 June 2026Retatrutide: Triple acting jab for type 2 diabetes lowers blood sugar and boosts weight loss, trial reportsRetatrutide
BMJ9 June 2026Brachial Plexopathy Following Rapid Weight Loss from Tirzepatide: A Case Report.Tirzepatide
Pain medicine case reports9 June 2026Compounded medicines requirements clarifiedSemaglutide
Medical Republic8 June 2026Early Generic Semaglutide in Canada — Implications for US Patients and PolicySemaglutide
JAMA Internal Medicine8 June 2026Apitegromab for lean mass preservation during tirzepatide-induced weight lossTirzepatide
Nature Medicine8 June 2026Once-Weekly Subcutaneous Semaglutide 2.4 mg Injection is Cost-Effective for Weight Management in SpainSemaglutide
Adv Ther6 June 2026Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trialRetatrutide
Lancet6 June 2026Synergistic Intervention for Obesity: Integrating Central Appetite Regulation and Peripheral Energy ExpenditureRetatrutide
Curr Obes Rep6 June 2026Steady-state pharmacokinetics of oral semaglutide using semi-mechanistic pharmacokinetic modelling and population simulationsSemaglutide
Xenobiotica6 June 2026Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like-Peptide-1 Use Following 10-Session Cognitive-Behavioural Therapy for Binge-Eating Disorder: A Single-Case Experimental DesignTirzepatide
Eur Eat Disord Rev6 June 2026Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trialTirzepatide
Lancet6 June 2026Dual GIP/GLP-1 receptor agonist tirzepatide ameliorates hepatic steatosis and inflammatory responses in a MASLD mouse model associated with the CCL2/CCR2 axisSemaglutide
BMC Gastroenterol5 June 2026Regulatory Notice
For informational purposes only. TGA scheduling may change without notice. All Schedule 4 peptides require a valid prescription from a registered Australian medical practitioner. This site does not sell, supply, or facilitate access to therapeutic goods. Data compiled from TGA SUSMP, public provider directories, and publicly available review platforms.